Scientific Rigor. Efficient Translation. Global Reach
A trusted pharmaceutical R&D and manufacturing partner serving global markets since 2005
Driving Global Generics, Pioneering Innovative Medicines
APIs · Formulation Development · Technology Transfer · DC & Premix · Finished Dosage Forms
Who We Are
Founded in 2005, Beijing HOPE Pharmaceutical Co., Ltd. is a national high-tech enterprise whose core competence lies in the seamless integration of chemical drug R&D with commercial API and finished-dose manufacturing. Ranked among the Top 50 Pharmaceutical R&D Companies in China, HOPE operates a full-value-chain ecosystem anchored by the HOPE Pharmaceutical Research Institute and three specialized subsidiaries: HMY Medical (Innovative & Generic Drug R&D), HMT Medical (API & Intermediate Operations), and HMYA Medical (International Business).
Backed by over two decades of industry leadership, our capabilities encompass chemical drug technology development, turn-key technology transfer, innovative drug incubation, MAH-based commercialization, and the global supply of high-purity APIs and advanced intermediates. Our formulation and filing expertise covers diverse dosage forms-including oral solids, liquids, inhaled aerosols, sterile injectables etc. - across key therapeutic areas such as oncology, psychiatry & neurology, cardiovascular & cerebrovascular, digestive, and respiratory diseases. Holding full independent import and export authorizations, HOPE is dedicated to delivering high-compliance, cost-effective pharmaceutical solutions to partners worldwide.
21+ Years of Pharmaceutical R&D Excellence
150+ Technology Transfers Completed
70+ Invention Patents Filed & Granted
40+ Product Series in Industrial Commercialization
Milestones
-
2026
Awarded the title of National High-tech Enterprise for nineteen consecutive years Named among the Top 50 Pharmaceutical R&D Companies of 2025–2026 Over 74 invention patents filed in total Over 150 technology transfers completed in total Multiple technological achievements commercialized; more than 40 series of products launched into industrial mass production
-
2025
Named among the Top 50 Pharmaceutical R&D Companies of 2024-2025 Four pharmaceutical formulation products approved for marketing Over 70 invention patents filed in total Over 140 technology transfers completed in total
-
2024
Awarded the title of 'National High-tech Enterprise' for 17 consecutive years Awarded the title of 'Top 20 Chinese Pharmaceutical R&D Companies' for 8 consecutive years Submitted registration applications for 10 formulation products in China, obtaining over 80 various registration approvals Obtained registration numbers for 10 active pharmaceutical ingredients from FDA, CDE, Taiwan Ministry of Health and Welfare, and other institutions Submitted 12 new patent applications, with a total of over 60 invention patents Achieved a cumulative factory technology transfer of over 130 items to client companies
-
2023
Awarded the title of 'National High-tech Enterprise' for 16 consecutive years Awarded the title of 'Top 20 Pharmaceutical R&D Companies in China' for 7 consecutive years Has obtained more than 70 clinical, production licenses, and new drug certificates approved by the National Medical Products Administration of China Has submitted more than 10 international registration applications to the FDA, EU, etc. Cumulatively achieved over a hundred technology transfers to client companies Completed multiple technology achievements transformation and industrialized production of over 30 series products
-
2022
More than 20 new invention patent applications Two raw material drug varieties registered with CDE transferred to A Five formulation varieties obtained production licenses Shanghai branch established to strengthen business expansion and layout
-
2021
Obtain the first CEP certificateObtain CNAS certification certificate First submission of MAH certification and obtain B certificate Two raw material drug varieties CDE transfer to A
-
2020
The R&D office building of Jinghai Industrial Park is officially in use.
-
2019
The subsidiary Haimei Ocean was established, and international business operates independently. Submitted registration applications to the EU and FDA Ranked among the top 20 pharmaceutical R&D companies in China for consecutive years Pilot unit for integration of informatization and industrialization Won the T100 New Technology and New Product Innovation Action Enterprise Award
-
2018
Establish a strategic partnership with PPC Jiaseng Consecutively ranked among the top 20 pharmaceutical R&D companies in China
-
2017
Establish a strategic partnership with Boteng Pharmaceutical Awarded the title of one of the top 20 pharmaceutical R&D companies in China
-
2016
The subsidiary Haimeiyuan was established, and the CRO business operates independently.
-
2015
The subsidiary Haimeitong was established, and the raw materials and intermediates business operates independently. Establish an employee stock ownership platform and complete the shareholding system transformation.
-
2011
Investing in Shandong Kongfu Pharmaceutical
-
2008
Establish a strategic partnership with Beihua Hengye
-
2006
Establish a new drug research and development center
-
2005
Established Haibu Pharmaceutical
Members of Group
HMY Medical
R&D of Innovative and Generic Drugs
HMT Medical
API & intermediate business
HMYA Medical
International business
© 2005–2026 Beijing HOPE Pharmaceutical Co., Ltd.
